Novo Nordisk Cuts 13,000 Jobs to Protect Margins Beyond Ozempic and Wegovy
The 2030 plan promises peer-like growth, more than five multi-blockbusters and a broadly stable adjusted operating margin. The harder task is replacing the profit pool created by Ozempic and Wegovy.
Novo Nordisk used its September 21 capital-markets day to define the economics it wants from the next four years: revenue growth roughly in line with large pharmaceutical peers while adjusted operating margin remains broadly stable.
Management wants to launch more than five multi-blockbusters by 2030, serve more than 60 million patients globally and generate more than DKr150 billion of risk-adjusted pipeline sales in 2035. The targets span obesity and diabetes as well as other therapeutic areas.
The cost base is already being reset. Novo has removed about 13,000 jobs over the past year under chief executive Mike Doustdar. Investors marked the shares down after the presentation, reflecting skepticism about how quickly new products can diversify a company still heavily exposed to semaglutide economics.
Oral Wegovy changes who pays
The Wegovy pill offers a useful view of Novo's commercial model. The company's second-quarter report says total prescriptions reached around 2.9 million in Q2 and more than 5 million since launch, with self-pay prices of $149 to $299 a month by dose.
Novo has separately described the majority of pill prescriptions as self-pay and its share of the U.S. oral-obesity market at roughly 90%. Those are different statistics: the 90% figure is market share, not the percentage of prescriptions paid in cash.
Direct payment can reach patients whose insurance coverage is poor and give Novo more control over distribution and pricing. It also exposes demand more directly to consumers' willingness to pay.
Novo's 2030 plan is ultimately a portfolio-productivity test. Restructuring can protect some margin and create room to fund R&D, but cost cuts cannot replace a maturing blockbuster franchise. The company needs enough new gross profit from oral GLP-1, next-generation obesity drugs and therapies outside diabetes and obesity to offset slower growth and future semaglutide patent erosion.
The targets are explicit. The investment case turns on how much pipeline revenue arrives early enough, and at what margin, to make diversification visible before the existing franchise loses its scarcity economics.
Sources
Novo Nordisk, “Highlights to be presented at Novo's Capital Markets Day 2026,” September 21, 2026 · Novo Nordisk, Q2 2026 financial report · Financial Times, “Novo sheds 13,000 jobs in a year,” September 21, 2026